MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4GlobeNewsWire • 04/20/22
MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC SpringGlobeNewsWire • 04/05/22
WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers NationwidePRNewsWire • 03/16/22
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsGlobeNewsWire • 02/28/22
Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of CareGlobeNewsWire • 02/16/22
MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28GlobeNewsWire • 02/14/22
Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect ReconstructionsGlobeNewsWire • 11/17/21
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and TendinopathyGlobeNewsWire • 11/01/21
MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3GlobeNewsWire • 10/20/21
Net Health Agreement with MIMEDX Streamlines Complex Insurance Benefits VerificationsPRNewsWire • 10/13/21
MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue TechnologyGlobeNewsWire • 09/13/21
MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/07/21